Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Robin Emsley
Sanja Kilian
Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

Abstract: The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the non-adherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperidone palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and comparable with other antipsychotics including risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research database and clinical experience with paliperidone and its parent compound risperidone, the availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer acting formulations in future), and the novel dose initiation procedure that provides rapid onset of action without the need for oral antipsychotic supplementation.

Keywords: paliperidone palmitate, long-acting antipsychotics, schizophrenia, relapse-prevention

Introduction
As a chronic and frequently debilitating brain disorder, schizophrenia is one of the leading contributors to the global disease burden. Despite its relatively low prevalence, the illness places an enormous emotional, health, social, and economic burden on patients, families, caregivers, and society. The course of schizophrenia is typically characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. There is also evidence for emergent treatment refractoriness, with relapse events possibly being the critical factor. Antipsychotic treatment is effective in reducing acute psychotic symptoms and for preventing relapse by way of maintenance treatment. Despite the demonstrated effectiveness of antipsychotics, the need for indefinite treatment has recently been questioned, due to the side effect burden of these drugs and a study suggesting that patients who undergo dose reduction or discontinuation may do better in the long term in terms of functional recovery. However, the effectiveness of maintenance antipsychotic treatment is extensively documented. Relapse rates are...
very high when treatment is discontinued, even after a single episode of psychosis, and good adherence and persistence with antipsychotics is associated with reduced hospitalization risk and lower total costs. Given the psychosocial and possible biological risks associated with discontinuation, most clinicians continue to encourage indefinite maintenance treatment.

While it is established that schizophrenia is a neurodevelopmental disorder, there is also evidence of illness progression after onset of the first psychotic episode. The illness trajectory has been proposed as having two phases. The first phase, comprising the early years, is when the illness is at its most aggressive, when relapses are most common, and where illness progression is most likely to occur. The second, chronic phase is when the illness has burnt itself out and patients stabilize insofar as acute psychotic episodes are less severe, although prominent deficits persist. Indeed, long-term data indicate that, even in patients who become relatively symptom free, psychosocial deficits are prominent and few achieve self-sufficiency and independent living.

The importance of early identification, effective intervention, and prevention of relapse in the early years of illness has been emphasized as the best strategy to minimize illness progression. First-episode patients are more responsive to acute treatment, although frequently the improvement is not maintained. This is consistent with a longitudinal study in patients with schizophrenia treated with oral antipsychotics where it was reported that, while 70% of participants met cross-sectional criteria for symptom remission at some time point in the study, only 23.6% maintained that status for 6 months or longer. This suggests that, in the early stages of illness, the challenge is not so much in achieving a treatment response, but in maintaining that status. Perhaps the most important barrier to optimal outcomes is nonadherence to and poor persistence with treatment. About 80% of patients experience multiple relapses over the first 5 years of treatment, and antipsychotic treatment discontinuation is by far the commonest predictor of relapse. The very high rates of discontinuation in studies such as the CATIE trial highlight the extent of the problem. While nonadherence and poor persistence is common in most chronic illnesses, the problem is compounded in schizophrenia where insight is impaired to the extent that there may be illness unawareness, symptom misattribution, and failure to recognize the need for treatment. For these reasons, psychosocial and pharmacological interventions have focused on ways of improving adherence and persistence. Long-acting injectable antipsychotics (LAIs) were developed in the 1960s specifically to address the nonadherence problem, and the older, first-generation depot antipsychotics were used extensively in many countries as an effective way of ensuring maintenance treatment. However, these agents were typically reserved for the chronic stage of illness, for patients who had proven themselves to be nonadherent to medication and after multiple relapses. In keeping with modern day public health principles, it makes sense rather to address nonadherence and poor persistence from the outset, thereby preventing accruing morbidity. Consequently, the use of LAIs as an early treatment option is increasingly considered. With the advent of the new generation oral antipsychotics two decades ago, it was hoped that these drugs would, by virtue of their more favorable tolerability profile, improve adherence and persistence. As a result, use of LAIs decreased. However, the newer oral antipsychotics failed to substantially improve adherence and reduce relapse rates. Subsequently, attention has again focused on developing LAI formulations, this time of the new generation antipsychotics. There are now LAI formulations for risperidone, olanzapine, aripiprazole, and paliperidone. The present selective review focuses specifically on paliperidone palmitate (PP), the LAI formulation of paliperidone. We conducted a Medline search using the search term “paliperidone palmitate”. References of the identified studies were cross-checked for additional relevant studies.

Pharmacology, mode of action, pharmacokinetics, and administration schedule

Paliperidone (9-hydroxyrisperidone) is the active metabolite of risperidone. Risperidone and paliperidone have similar receptor binding profiles, although there are some differences. While paliperidone antagonizes central dopamine D2 and serotonin 5-HT2A receptors as well as alpha1- and alpha 2-adrenergic receptors and H1 histaminergic receptors, the risperidone 5-HT2A/D2 binding ratio is significantly lower than that of paliperidone. Also, a hydroxyl group in the paliperidone molecule confers increased hydrophilicity that contributes to differential effects on mitochondrial movement, protein expression, and phosphorylation. Further, paliperidone may be less able to enter the brain due to its greater affinity for the transporter P-glycoprotein. Whether these pharmacological differences result in clinical differences is not established. Renal excretion is the major route of paliperidone elimination. As such, PP is not recommended in patients with moderate or severe renal impairment. In vitro studies in human liver microsomes found that paliperidone does not substantially inhibit the...
metabolism of medicines metabolized by cytochrome P450 isoforms, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, in contrast to risperidone, no dose adjustment is required for patients with mild to moderate hepatic impairment, and being a CYP2D6 poor metabolizer may not be clinically relevant for paliperidone treatment.22

PP is the palmitate ester of paliperidone, provided as a nanocrystal suspension in an aqueous vehicle for parenteral administration. Due to its low water solubility, PP dissolves slowly after intramuscular injection before being hydrolyzed to paliperidone and absorbed into the systemic circulation. PP may be administered either as gluteal or as deltoid intramuscular injection. The original once-monthly injectable formulation of PP (PP-1M) was approved by the US Food and Drug Administration (FDA) in 2009 and is marketed as Invega Sustenna® (Janssen Pharmaceutica NV, Beerse, Belgium) in the United States and as Xeplion® (Janssen Pharmaceutica NV) in Europe. Mean Cmax was higher after deltoid injection than after gluteal injection (except for the 100 mg equivalent [eq.] dose), although the area under the curve extrapolated to infinity divided by weight (AUC∞) for both injection sites was comparable at all doses. Median time to reach Cmax ranged from 13 to 14 days after deltoid and 13 to 17 days after gluteal injection across all doses.21

The recommended initiation of PP is with a dose of 150 mg on treatment day 1 and 100 mg 1 week later (day 8), both administered in the deltoid muscle in order to attain rapid therapeutic concentrations. The third dose should be administered 1 month after the second initiation dose. The recommended monthly maintenance dose is 75 mg, and the recommended dose range is 25–150 mg. Patients who are overweight or obese may require doses in the upper range. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle.21

**Randomized, controlled trials vs placebo for acute, symptomatic schizophrenia**

Efficacy and safety of flexible doses of PP-1M was demonstrated in four short-term double-blind, placebo-controlled, randomized, controlled trials (RCTs) (Table 1). In a Phase 2b study over 9 weeks, acutely symptomatic participants (n=197) received gluteal injections of PP (fixed doses of 50 or 100 mg eq.) or placebo on days 1, 8, and 36. Positive and Negative Syndrome Scale (PANSS) total scores improved significantly at end point for both doses (P<0.01) vs placebo. Fewer PP-treated (2%) vs placebo-treated (10%) patients discontinued the study due to emergent adverse events reported more frequently in the PP groups than with placebo. Only 30 participants were randomized to the 150 mg eq. dose group, and definitive conclusions could not be drawn from the results of that group.

| Source | Brief description of study | Follow-up period | Treatment/intervention | Sample size | Treatment intervention | Outcomes |
|--------|---------------------------|------------------|------------------------|-------------|-----------------------|----------|
| Kramer et al (2010)* | RCT comparing PP-1M/placebo | 9 weeks | PP dosage of 50 or 100 mg eq. received (gluteal) on days 1, 8, and 36 or placebo | 197 | | PANSS total scores improved for both doses (P<0.001) vs placebo |
| Nasrallah et al (2010)* | RCT comparing PP-1M/placebo | 13 weeks | PP dosage of 25, 50, and 100 mg eq. received (gluteal) on days 1 and 8, then every 4 weeks (ie, on days 16 and 64). | 207 | | Fewer PP-treated (25%) vs placebo-treated (10%) patients discontinued the study due to emergent adverse events |
| Gopal et al (2010)* | RCT comparing PP-1M/placebo | 13 weeks | PP dosage of 50, 100, or 150 mg eq. received (gluteal) monthly after two initial doses given 1 week apart or placebo | 388 | | PP-treated patients experienced more parkinsonism than placebo |
| Panesar et al (2010)* | RCT comparing PP-1M/placebo | 13 weeks | PP dosage of 50, 100, or 150 mg eq. received (gluteal) every 4 weeks | 228 | | As were changes in parkinsonism and BMI |

(Continued)
### Table 1 (Continued)

| Source | Brief description of study | Follow-up period | Sample size, N | Treatment/intervention | Outcomes |
|--------|---------------------------|-----------------|----------------|------------------------|----------|
| Pandina et al (2010) | RCT comparing PP-1M/placebo | 13 weeks | 652 | PP dosage of 150 mg eq. received (deltoid) on day 1 and dose of 25, 100, or 150 mg eq. on day 8 and then once monthly thereafter, or placebo | • PANSS total improved significantly ($P<0.03$) in all the PP dose groups vs placebo. • Treatment-emergent adverse events that occurred more frequently in the PP group vs the placebo group were injection-site pain (7.6% vs 3.7%), dizziness (2.5% vs 1.2%), sedation (2.3% vs 0.6%), pain in the extremity (1.6% vs 0.0%), and myalgia (1.0% vs 0.0%). |
| Alphs et al (2011) | NA | NA | 312 | NA | • In post hoc analysis in subgroup ($n=312$), compared with placebo, PP improved psychotic symptoms by day 4 and after subsequent injections, dose-dependent improvements persisted. • Time to relapse was significantly delayed for PP ($P<0.0001$) for the interim ($n=312$) and final analysis ($n=408$). • Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. • The incidence of glucose-related adverse events was low (<4%). • Injection site tolerability was comparable between groups. |
| Hough et al (2010) | Relapse-prevention RCT comparing PP-1M/placebo | Phase I (up to 7 days screening) | 951 | NA | • Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. |
| Hough et al (2010) | Relapse-prevention RCT comparing PP-1M/placebo | Phase II (9 weeks OL switching) | 849 | PP dosages of 25, 50, or 100 mg eq. received after initial PP 50 mg eq. on day 1 and day 8 | • Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. |
| Hough et al (2010) | Relapse-prevention RCT comparing PP-1M/placebo | Phase III (24 weeks OL maintenance) | 681 | PP flexi dosages of 25, 50, or 100 mg eq. received for first 12 weeks and for last 12 weeks maintenance dose received | • Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. |
| Hough et al (2010) | Relapse-prevention RCT comparing PP-1M/placebo | Phase IV (DB) | 410 | PP at the previously established stabilized dose received, or placebo | • Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. |
| Hough et al (2010) | Relapse-prevention RCT comparing PP-1M/placebo | Phase V (OLE) | 176 (patients receiving PP and placebo, respectively, completed OLE) | NA | • Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. |
| Gopal et al (2011) | Study reporting on Phase V (OLE) of Hough et al (2010) | 1 year | 288 | PP flexi dosages of 25, 50, 75, or 100 mg eq. received (gluteal) and paliperidone ER 3 mg tablets | • Most frequently reported adverse events were insomnia (7%), worsening of schizophrenia, nasopharyngitis, headache and weight increase (6% each). • Potentially prolactin-related adverse events occurred in 3% of patients, mostly women. • EPS were reported in 6% of patients. • At end point, investigator-rated redness at the injection site was observed in ≤4% of patients and injection site pain was absent in 82%–87% of patients. |
| Fu et al (2017) | RCT comparing PP-1M/placebo | Phase I (25 weeks OL) | 667 | Subjects were treated with PP-1M either as monotherapy or in combination with antidepressants or mood stabilizers | • Improvements in all PSP domains were observed during the open-label phase and were maintained during the double-blind phase with PP but not with placebo. |
| Fu et al (2017) | RCT comparing PP-1M/placebo | Phase II (15 months DB relapse prevention) | 334 | Stabilized subjects received PP-1M or placebo | • Improvements in all PSP domains were observed during the open-label phase and were maintained during the double-blind phase with PP but not with placebo. |

**Notes:** a Phase 2b study; b two-hundred and eighty-eight of 388 enrolled patients completed the open-label extension.

**Abbreviations:** eq., equivalent; RCT, randomized controlled trial; PP, paliperidone palmitate; PP-1M, paliperidone palmitate once-monthly; PANSS, Positive and Negative Syndrome Scale; CGi, Clinical Global Impression Severity Scale; PSP, Personal and Social Performance Scale; ePS, emergent extrapyramidal symptoms; OL, open-label; OLE, open-label extension; DB, double blind; ER, extended-release; BMI, body mass index; NA, not applicable.
 Randomized, controlled trial vs placebo for maintenance treatment

Efficacy of PP-1M vs placebo in relapse prevention was assessed in a complex study design. Patients with a PANSS total score <120 were transitioned from previous antipsychotics to PP during a 9-week, open-label phase. Two intramuscular injections of 50 mg eq. PP were given 1 week apart, followed by flexibly dosed monthly injections (25, 50, or 100 mg eq.). Stable patients (PANSS total score ≤75) then entered a 24-week maintenance phase, following which they were randomized to either continue PP at the stabilized dose or begin placebo in the double-blind phase. Time-to-relapse, the primary end point, was significantly delayed for PP (P<0.0001) for the interim (n=312) and final analysis (n=408). Across the phases, mean weight increased by 1.9 kg for PP while it remained unchanged for placebo patients. The incidence of glucose-related adverse events was low (≤4%). Injection site tolerability was comparable between groups.29

In a 1-year open-label extension to this study, the safety and tolerability of PP were assessed. Patients received gluteal injections of PP-1M starting at 50 mg eq., followed by flexible dosing of 25, 50, 75, or 100 mg eq. Two-hundred and eighty eight of the 388 enrolled patients completed the open-label extension. The most frequently reported adverse events were insomnia (7%), worsening of schizophrenia, nasopharyngitis, headache, and weight increase (6% each). Potentially, prolactin-related adverse events occurred in 3% of patients, who were mostly women. Emergent extrapyramidal symptoms (EPS) were reported in 6% of patients. At the end point, investigator-rated redness at the injection site was observed in ≤4% of patients and injection site pain was rated by investigators as absent in 82%–87% of patients.30

A RCT evaluated the effect of PP-1M on the PSP scale in patients with schizoaffective disorder experiencing an acute exacerbation of psychotic and mood symptoms. Subjects were treated with PP-1M either as monotherapy or in combination with antidepressants or mood stabilizers during a 25-week open-label phase (n=667), and stabilized subjects (n=334) were randomly assigned to PP-1M or placebo in a 15-month double-blind relapse-prevention phase. Improvements in all PSP domains were observed during the open-label phase and were maintained during the double-blind phase with PP but not with placebo.31

Comparative randomized, controlled trials

PP-1M vs risperidone long-acting injectable

A 53-week, Phase III RCT was designed to assess the noninferiority of PP-1M to risperidone long-acting injectable (RLAI) in 747 patients with schizophrenia. Acutely symptomatic patients (n=749) were randomized to gluteal
injections of either PP 50 mg eq. on days 1 and 8, followed by flexible dosing (25–100 mg eq.) once-monthly, or RLAI 2-weekly, 25 mg on days 8 and 22 followed by flexible dosing (25–50 mg) starting from day 36, with oral risperidone supplementation. Mean (SD) change from baseline to end point in PANSS total score was −11.6 (21.22) for PP and −14.4 (19.76) for RLAI, and least-squares means difference was −2.6 (95% CI: −5.84, 0.61). PP’s failure to demonstrate comparable efficacy to RLAI was attributed to the suboptimal initiation dosing regimen which resulted in lower median plasma levels of the active moiety in PP-treated patients. Tolerability profiles of both treatments were comparable to previous studies.

Another RCT, also designed to assess noninferiority of PP vs RLAI, was conducted in 1,220 patients with schizophrenia over 13 weeks. The dosing regimen for the PP arm was as follows: deltoid injections on day 1 (150 mg eq.), day 8 (100 mg eq.), and flexible dosing as deltoid or gluteal injections on day 36 (50 mg eq. or 100 mg eq.) and day 64 (50 mg eq., 100 mg eq., or 150 mg eq.). For the RLAI arm, patients received gluteal injections on days 8 and 22 (25 mg), days 36, 50 (25 or 37.5 mg), and days 64, 78 (25, 37.5, or 50 mg), and oral supplementation with risperidone on days 1 to 28. Mean (SD) PANSS total score change from baseline to end point decreased similarly in both groups: PP (−18.6 [15.45]) and RLAI (−17.9 [14.24]). PP treatment was noninferior to RLAI (point estimate [95% CI]: 0.4 [−1.62, 2.38]). The tolerability and safety of PP was generally similar to that of RLAI. This dosing regimen subsequently became the recommended initiation dosing procedure for PP-1M. In a post hoc subgroup analysis in markedly to severely ill subjects (n=292) from this study, PANSS total scores improved significantly in both arms, starting from day 4 through to end point; and in another post hoc, subgroup analysis from this study, no significant differences in the mean weight change, most metabolic parameters, or mean efficacy measures were observed over the 13 weeks of treatment.

An open-label, rater-blinded, RCT evaluated noninferiority of PP-1M to 2-weekly RLAI in 452 Chinese patients with acute schizophrenia. PP-treated patients received deltoid injections on day 1 (150 mg eq.) and day 8 (100 mg eq.), and then once-monthly deltoid or gluteal injections, flexibly dosed (50, 100, or 150 mg eq.). RLAI-treated patients received 2-weekly gluteal injections, flexibly dosed (25, 37.5, or 50 mg), and oral risperidone supplementation at initiation and with RLAI dose increases. Mean (SD) change from baseline to end point in PANSS total scores was −23.6 (16.28) for the PP group and −26.9 (15.43) for RLAI group. PP was noninferior to RLAI (least-squares mean difference [95% CI]: −2.3 [−5.20, 0.63]). The incidence of treatment-emergent adverse events was similar between the two groups. The most common adverse events were akathisia, tremor, and insomnia.

A 6-month, open-label RCT compared the effects of RLAI and PP-1M on social functioning in a small sample of patients with schizophrenia (n=30). The PP-treated patients showed a greater degree of total social functioning, independent life competence, and performance as compared to the RLAI group. In the same sample, effects of PP-1M and RLAI on cognitive functions were compared. The results suggested that PP might improve attention and processing speed more than RLAI. A pragmatic, randomized, open-label, flexible dose study compared PP-1M (n=226) with oral antipsychotics (n=218) over 15 months in patients with schizophrenia and a history of contact with the criminal justice system. The mean cumulative function of treatment failure events and institutionalizations differed significantly in favor of PP compared with oral antipsychotics (P=0.007 and P=0.005, respectively). To assess patient satisfaction with switching from oral antipsychotics to a long-acting injectable antipsychotic formulation, a 21-week, open-label RCT was conducted in 154 patients with schizophrenia dissatisfied with current oral atypical antipsychotics. Participants were randomized to either immediate or delayed switching to PP-1M. Medication satisfaction improved significantly in both groups, with comparable efficacy and tolerability (Table 2).

**PP-1M vs aripiprazole once-monthly 400 mg**

A randomized, noninferior, open-label, rater-blinded, head-to-head comparison of PP-1M and aripiprazole once-monthly 400 mg (AOM 400) was conducted over 28 weeks in 295 patients with schizophrenia, with the Heinrichs–Carpenter Quality-of-Life Scale (QLS) score as the primary outcome. Sixty-eight percent of AOM 400 and 57% of PP patients completed 28 weeks of treatment. AOM-treated patients showed significantly greater improvements in the QLS total score (4.67 [95% CI: 0.32, 9.02], P=0.04). There were also significantly greater improvements in CGI Severity scale and the Investigator’s Assessment Questionnaire for AOM 400 vs PP. Common treatment-emergent adverse events in the treatment continuation phase were more frequent with PP vs AOM 400.

**PP-1M vs haloperidol decanoate**

A double-blind RCT was conducted in 311 patients with schizophrenia or schizoaffective disorder who were clinically...
## Table 2 Summary of comparative randomized, controlled trials for once-monthly paliperidone palmitate

| Source (year) | Brief description of study | Follow-up period | Sample size, N | Treatment/intervention | Outcomes |
|---------------|-----------------------------|------------------|----------------|------------------------|----------|
| Fleischhacker et al (2012) | RCT comparing PP-1M/RLAI-1M | 53 weeks | 747 | Acutely symptomatic patients received PP dosage of 50 mg eq. on days 1 and 8, followed by flexible dosing (25–100 mg eq.) once-monthly, or RLAI 2-weekly, 25 mg on days 8 and 22 followed by flexible dosing (25–50 mg) starting from day 36, with oral risperidone supplementation | • Mean (SD) change from baseline to end point in PANSS total score was −11.6 (21.22) for PP and −14.4 (19.76) for RLAI.  
• PP’s failure to demonstrate comparable efficacy to RLAI was attributed to the suboptimal initiation dosing regimen which resulted in lower median plasma levels of the active moiety in PP-treated patients. |
| Pandina et al (2011) | RCT comparing PP-1M/RLAI-1M | 13 weeks | 1,220 | PP dosage received (deltoid) of 150 mg eq. on day 1 and 100 mg eq. on day 8. Flexible dosing of 50 mg or 100 mg eq. (deltoid or gluteal) on day 36 and day 64. Or RLAI dosage received (gluteal) of 25 mg on days 8 and 22; 25 or 37.5 mg on days 36 and 50; 25, 37.5, or 50 mg on days 64 and 78; and oral supplementation with risperidone on days 1 to 28 | • Mean PANSS total score change from baseline to end point decreased similarly in both groups.  
• PP treatment was noninferior to RLAI.  
• The tolerability and safety of PP was generally similar to that of RLAI.  
• PANSS total scores improved significantly in both arms from day 4 through to end point. |
| Fu et al (2014) | Post hoc subgroup analysis in markedly to severely ill subjects drawn from Pandina et al (2011) | 292 | • PANSS total scores improved significantly in both arms from day 4 through to end point. |
| Li et al (2011) | OL RCT comparing PP-1M/2-weekly RLAI | 13 weeks | 452 | PP dosages received (deltoid) of 150 mg eq. on day 1 and 100 mg eq. on day 8, then once-monthly flexible dosages of 50, 100, or 150 mg eq. received (deltoid or gluteal). Or RLAI 2-weekly received (gluteal) of fixed doses of 25, 37.5, or 50 mg, and oral risperidone supplementation at initiation and with RLAI dose increase | • Mean (SD) change from baseline to end point in PANSS total scores was −23.6 (16.28) for the PP group and −26.9 (15.43) for the RLAI group.  
• PP was noninferior to RLAI (least-squares mean difference [95% CI]: −2.3 [−5.20, 0.63]).  
• The incidence of treatment-emergent adverse events was similar between the two groups.  
• The most common adverse events were akathisia, tremor, and insomnia.  
• The PP-treated patients showed greater degree of total social functioning, independent life competence, and performance as compared to the RLAI group.  
• The results suggested that PP might improve attention and processing speed more than RLAI. |
| Koshikawa et al (2016) | OL RCT comparing effect of PP-1M/RLAI on social functioning | 6 months | 30 | Patients previously treated with RLAI continued with RLAI or received PP | |
| Takekita et al (2016) | In the same sample as Koshikawa et al (2016), cognitive functioning was assessed | 334 | No significant differences in the mean weight change, most metabolic parameters, or mean efficacy measures were observed. |
| Source           | Brief description of study                                                                 | Follow-up period | Sample size, N | Treatment/intervention                                                                 | Outcomes                                                                                                                                 |
|------------------|-------------------------------------------------------------------------------------------|------------------|----------------|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Alphs et al (2016) | Pragmatic, OL RCT comparing PP-1M/OA                                                      | 15 months        | 444            | Monthly injectable PP (78–234 mg) or daily OA                                          | • The mean cumulative function of treatment failure events and institutionalizations differed significantly in favor of PP compared with oral antipsychotics \((P=0.007)\) and \((P=0.005)\), respectively.  
• Medication satisfaction improved significantly in both groups, with comparable efficacy and tolerability. |
| Kwon et al (2015)  | OL RCT assessing patient satisfaction with switching from OA to PP-1M                    | 21 weeks         | 154            | Immediate switch group received PP dosages of 150 mg eq. on day 1 and 100 mg eq. on day 8, and for later visits the recommended dose was 75 mg eq. or 25, 50, 75, 100, or 150 mg eq. The delayed switch group was maintained on current OA from days 1–56 and received PP dosages of 150 mg eq. on day 57 and 100 mg eq. on day 64, and for later visits the recommended dose was 75 mg eq. or 25, 50, 75, 100, or 150 mg eq.                                                                 |                                                                                                                                 |
| Naber et al (2015) | OL RCT comparing PP-1M/AOM\(^a\)                                                          | 28 weeks         | 295            | PP dosages of 50–150 mg eq. received per month, or AOM 400 mg                          | • AOM-treated patients showed significantly greater improvements in the QLS total score (4.67 [95% CI: 0.32, 9.02], \(P=0.04\)).  
• Greater improvements in CGI Severity scale and the Investigator’s Assessment Questionnaire for AOM 400 vs PP.  
• Common treatment-emergent adverse events in the treatment continuation phase were more frequent with PP vs AOM 400.  
• There was no statistically significant difference in the rate of efficacy failure for PP-1M compared with haloperidol decanoate (adjusted hazard ratio: 0.98; 95% CI: 0.65, 1.47).  
• Forty-nine (33.8%) patients in the PP group and 47 (32.4%) in the haloperidol decanoate group experienced efficacy failure.  
• Patients in PP group gained weight and those in the haloperidol decanoate group lost weight.  
• PP patients had higher maximum mean levels of serum prolactin while haloperidol decanoate treated patients had greater increases in global ratings of akathisia.  
• PP-1M was associated with 0.0297 greater quality-adjusted life years over 18 months \((P=0.03)\) but with higher average costs for inpatient and outpatient services and medication compared with haloperidol decanoate \((P<0.001)\). |
| McEvoy et al (2014) | RCT comparing PP-1M/haloperidol decanoate                                                  | 24 months        | 311            | PP dosages received (deltoid) of 234 mg on day 1 and 156 mg on day 8, and 117 mg received (deltoid or gluteal) once-monthly thereafter. Haloperidol decanoate dose of 50 mg received (deltoid) on days 1 and 8, 75 mg on days 28 and 56, and 50 mg received (deltoid or gluteal) once-monthly thereafter |                                                                                                                                 |
| Rosenheck et al (2016) | Cost-effectiveness study conducted in the same cohort as McEvoy et al (2014)\(^a\)         |                  |                |                                                                                                                                              |                                                                                                                                 |
Paliperidone palmitate in schizophrenia

**Neuropsychiatric Disease and Treatment** 2018:14

---

**Table 1: Studies Assessing Paliperidone Palmitate (PP) vs Oral Antipsychotics (OA)**

| Study | Type of Study | Duration | Sample Size | Key Findings |
|-------|---------------|----------|-------------|--------------|
| Schreiner et al (2015) | Rater-blinded RCT comparing PP-1M/OA | 24 months | 715 | PP doses of 150 mg eq. received (deltoid) on day 1, 100 mg eq. received (deltoid) on day 8, 75 mg eq. on day 38 (deltoid or gluteal), thereafter 25–150 mg eq. (deltoid or gluteal) or OA |
| Gopal et al (2017) | Pooled analysis of two RCTs (PP-1M and PP-3M) assessing predictors of caregiver burden | NA | 1,498 | NA |

**Note:** Phase 3b study.

**Abbreviations:** eq., equivalent; RCT, randomized controlled trial; PP, paliperidone palmitate; PP-1M, paliperidone palmitate once-monthly; PP-3M, paliperidone palmitate 3-monthly; RLAI, risperidone long-acting injection; AOM, aripiprazole once-monthly; OA, oral antipsychotic; PANSS, Positive and Negative Syndrome Scale; CGI, Clinical Global Impression Severity Scale; QLS, Heinrichs-Carpenter Quality-of-Life Scale; OL, open-label; OLE, open-label extension; NA, not applicable.

---

In a naturalistic study conducted over 1 year to determine the factors predicting continuation with PP treatment (n=200), Schreiner et al (2015) assessed PP-1M vs OA to compare the effectiveness of PP-1M vs haloperidol decanoate.

1. **Time to relapse** was significantly longer in the PP-1M (n=352) compared with the oral antipsychotics arm (n=363), with 85% relapse-free survival at 469 days for PP-1M patients vs 249 days for oral antipsychotics patients (P=0.02).
2. There were significantly fewer relapses in the PP-1M group (14.8% vs 20.9%; P=0.03), representing a 29.4% relative risk reduction. Improvements in functionality were comparable between treatment arms.
3. Caregiver burden was significantly improved for patients on prior oral antipsychotics after switching to PP.

**PP-1M vs Oral Antipsychotics in Recent-onset Schizophrenia**

Schizophrenia patients assessed to be at risk of relapse, for up to 24 months, to compare the effectiveness of PP-1M vs haloperidol decanoate.

An RCT assessed the efficacy of PP-1M vs physician's choice of oral antipsychotics for relapse prevention in patients with a recent diagnosis of schizophrenia (within 5 years). Patients who met predefined response criteria were entered into the 24-month rater-blinded treatment phase. Time to relapse was significantly longer in the PP-1M group (n=352) compared with the oral antipsychotics arm (n=363). There were significantly fewer relapses in the PP-1M group (14.8% vs 20.9%; P=0.03), representing a 29.4% relative risk reduction. Improvements in functionality were comparable between treatment arms.

PP-1M was associated with 0.0297 greater quality-adjusted life years over 18 months (P=0.03), but with higher average costs for inpatient and outpatient services and medication compared with haloperidol decanoate (P<0.001). Gopal et al (2017) in a pooled analysis of two RCTs (PP-1M and PP-3M) assessing predictors of caregiver burden, caregivers were significantly improved for patients on prior oral antipsychotics after switching to PP. Schreiner et al (2015) in a phase 3b study. The primary outcome measure was efficacy defined as a psychiatric hospitalization, a need for crisis stabilization, or being assessed to be at risk of relapse, for up to 24 months, to compare the effectiveness of PP-1M vs haloperidol decanoate.
neurocognitive function and functional outcome were significantly improved after switching (P < 0.0001). In the study's end point analysis, there was significantly less symptomatic relapse in the PP-1M group compared with the oral antipsychotic group (P = 0.0001). Significant improvements in PANSS total score were observed after switching (P < 0.0001), as did PSP scores (P < 0.0001). Combination therapy was generally well tolerated, with the exception of neurological adverse events, which included akathisia (40.8%), akinesis (20.8%), and tremor (8.4%). In a smaller sample, prolactin levels were significantly lower in the PP-1M cohort than in the oral antipsychotic cohort (P = 0.0001). A retrospective mirror-image observational study assessed the effects of PP-1M on the frequency of hospitalization rates in 66 patients with schizophrenia who had received PP-1M for at least 1 year. The mean number of acute admissions fell from 0.86 in the year before PP initiation to 0.23 in the following year (P < 0.001). A single-arm, multicenter, open-label, 6-month study in patients with schizophrenia assessed the tolerability, safety, and efficacy of flexible doses of PP-1M in a subset of nonadherent patients (n = 593). PANSS total scores decreased from 71.5 (14.6) at baseline to 59.7 (18.1) at end point (P < 0.0001). PSP scores improved significantly from baseline to end point (P < 0.0001). In the same study, but assessing only patients who switched to PP-1M after unsuccessful treatment with RLAI or conventional depot antipsychotics (n = 231), significant reductions in PANSS total scores were observed after switching (P = 0.01). A third subset analysis of the same study was conducted in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics who were switched to PP-1M (n = 212). Significant improvements in PANSS total score were observed from day 8 onwards (P < 0.0001). PP was also associated with significant improvements in secondary measures of symptom severity, subjective well-being, medication satisfaction, illness-related disorders of activity and participation, and patient functioning (P < 0.0001). PP was generally well tolerated, with significant reductions in Extrapyramidal Symptom Rating Scale total score (P < 0.0001). A 25-week, open-label study evaluated safety and efficacy of PP-1M in 353 Chinese patients with schizophrenia. PANSS total scores improved significantly (P < 0.0001), as did PSP scores (P < 0.0001). Most frequently reported emergent adverse events were extrapyramidal disorder (15.3%), akathisia (10.5%), blood prolactin increase (8.8%), and insomnia (5.4%). Eight deaths were reported, including four completed suicides. A prospective observational study over 3 months assessed the effect of switching from RLAI to PP-1M on sexual function and prolactin levels in a small sample (n = 11) of patients with psychosis who developed hyperprolactinemia on RLAI and who were then switched to PP. There was a significant decrease in serum prolactin levels (P = 0.04) and a fourfold reduction in clinically significant sexual dysfunction. A retrospective, observational cohort study using patient claims data compared effectiveness evidence for PP-1M vs oral atypical antipsychotics. Emergency room visits and hospitalization rates were lower in PP-1M patients, although hospitalizations did not achieve statistical significance. In an observational study, 200 consecutive patients prescribed PP in normal practice were followed up. After 1 year, 65% of patients were still receiving PP. The number of admissions to hospital in the year following PP initiation was 0.49/patient compared with 0.69/patient/year for the 3 years before initiation (P = 0.0001). The median number of bed days for the 3 years before PP initiation was 21.50/year and in the year following PP initiation, it was 0.58. In a noninterventional, observational study of consecutive patients treated with PP-1M (n = 300), 38.7% completed 2 years of continuous treatment and a further 7.6% patients discontinued PP but restarted after >2 months. Prior treatment with risperidone reduced the risk of discontinuation by 39% (P = 0.004) and having treatment initiated as an outpatient by 49% (P = 0.001). The risk of discontinuation was
increased by 63% when the reason for prescribing PP was poor tolerability of the prior treatment \((P=0.028)\).99

A part-prospective mirror-image study examined outcomes 2 years before starting PP-1M and 2 years after (n=225). At study end point, 41.8% of patients were still receiving PP-1M. The number of admissions fell from 1.80 in the 2 years before starting PP-1M to 0.81 in 2 years following initiation or discharge \((P<0.001)\). Total bed days were reduced from 79.6 in the 2 years before to 46.2 in the 2 years after initiation or discharge \((P<0.001)\).80

The relapse risk following a switch from RLAI to PP-1M (n=188) vs a switch from RLAI to oral antipsychotics (n=131) was examined using information from a Medicaid database. Patients who switched from RLAI to PP had fewer events (hospitalization or emergency room visit) \((26 \text{ vs } 32)\), longer time to an event \((70 \text{ vs } 47 \text{ days})\), and lower risk of relapse \((P=0.02)\) compared with those who switched from RLAI to oral antipsychotics.61

A naturalistic cohort of all identifiable patients who initiated PP-1M in a specific region in the United Kingdom \((n=179)\) was assessed. Sixty percent of patients continued PP-1M beyond 12 months. Schizophrenia diagnosis, fewer inpatient days after initiation, dose adjustment up or down, and a higher maintenance dose were associated with treatment continuation.62

In an 18-month, open-label, noncomparative study from the Asia-Pacific region, patients with recent-onset schizophrenia \((\leq 5 \text{ years})\) who were unsatisfactorily treated with previous oral antipsychotics \((n=521)\) were treated with flexible doses of PP-1M. PANSS total scores improved significantly \((P<0.0001)\). There were greater improvements among patients with more severe symptoms. In a mirror analyses subset \((n=474)\), PP significantly reduced mean number of hospitalization days/person/year as well as percentage of patients requiring hospitalization in past 12 months \((P<0.0001)\). Adverse events \((\geq 15\%)\) were EPS \((31.3\%)\), injection site pain \((18.6\%)\), and insomnia \((15.2\%)\).63

A retrospective claims-based analysis of Medicaid patients with schizophrenia compared all-cause health care utilization and costs between patients treated with PP-1M \((n=722)\) vs atypical oral antipsychotics \((n=722)\). Over 12 months, PP-1M patients were less likely to discontinue treatment \((30.6\% \text{ vs } 39.5\%, \ P<0.001)\) or switch to a new therapy \((21.6\% \text{ vs } 27.7\%, \ P=0.007)\) and had fewer inpatient visits \((5.0 \text{ vs } 7.9, \ P<0.001)\), lower mean hospitalization days \((15.0 \text{ vs } 27.7 \text{ days}, \ P<0.001)\), and inpatient costs \((\$5,060 \text{ vs } \$10,880, \ P=0.001)\). Pharmacy costs were significantly higher in the PP-1M cohort \((P<0.001)\), although total costs were not significantly different \((P=0.853)\).64 Another study in patients recently diagnosed with schizophrenia compared adherence, health care resource utilization, and Medicaid spending between schizophrenia patients treated with PP-1M \((n=2,053)\) vs those treated with oral atypical antipsychotics \((n=22,247)\). Patients treated with PP-1M had better adherence \((P<0.001)\) and required less use of concomitant psychiatric medications. Lower medical costs associated with PP-1M outweighed the higher pharmacy costs, with similar total health care costs across the groups.65

An international, multicenter, retrospective chart review of medical records of adult patients who were newly diagnosed \((<1 \text{ year})\) with schizophrenia and who had received continuous treatment with PP-1M for \(\geq 12 \text{ months} \) in naturalistic clinical settings \((n=84)\) was undertaken. Of the patients, 79.2% had \(\geq 20\%\) improvement and 47.2% had a \(\geq 50\%\) improvement in PANSS total scores. PSP scores improved significantly in 53.3%. Most adverse drug reactions were mild or moderate in severity \((Table 3)\).66

Three-monthly paliperidone palmitate

In 2015, a new formulation, 3-monthly injection of prolonged release suspension of PP (PP-3M), was approved for the maintenance treatment of schizophrenia in adult patients by the European Medicines Agency \((Trevicta^\circledR, Janssen Pharmaceutica NV)\), following earlier approval in the United States by the Food and Drug Administration \((Invega Trinza^\circledR, Janssen Pharmaceutica NV)\). Pharmacokinetic studies support the feasibility of administering PP on a 3-monthly basis, subsequent to stabilization of treatment with the administration of four once-monthly injections of PP-1M, at doses 3.5 times higher than the last dose of PP-1M. The dose range for PP-3M is 175, 300, 450, and 525 mg eq.67

A relapse-prevention RCT compared PP-3M to placebo in 506 patients with schizophrenia. The trial comprised four phases, namely a 3-week screening phase; a 17-week, flexible-dose, open-label transition phase; a 12-week open-label maintenance phase; and an open-ended double-blind phase. Patients received once-monthly doses of PP-1M \((50, 75, 100, \text{ or } 150 \text{ mg eq.})\) during the transition phase, followed by a single dose of PP-3M (at 3.5 times the stabilized dose of PP-1M) during the maintenance phase. Stable patients were then randomized to receive either a fixed dose of PP-3M \((175, 263, 350, \text{ or } 525 \text{ mg eq.})\) or placebo once every 3 months during the double-blind phase. In the preplanned interim analysis, time to relapse was significantly longer in the PP-3M group vs the placebo group \((P<0.001)\). PANSS total score and factor analysis derived
| Source | Brief description of study | Follow-up period | Sample size, N | Treatment/intervention | Outcomes |
|--------|---------------------------|-----------------|----------------|------------------------|----------|
| Attard et al (2014) | Naturalistic study focusing on factors predicting continuation with PP | 1 year | 200 | NA | • Initiation as an outpatient ($P=0.001$), being switched from risperidone ($P=0.03$), and correct initiation dosing ($P=0.02$) were significantly associated with a lower likelihood of discontinuation. |
| Hargarter et al (2017) | Naturalistic study exploring efficacy, safety, and tolerability of PP-1M initiated shortly after hospital admission | 6 weeks | 367 | NA | • Significant improvements were observed in psychotic symptoms ($P<0.0001$) and PSP scores ($P<0.0001$). • Treatment was well tolerated. |
| Baser et al (2015) | Study comparing real-world health care costs and resource utilization between SZ patients treated with PP-1M and OA | NA | 335 | NA | • Patients treated with PP had lower inpatient costs and admission rates, although total health care costs were not significantly different. |
| Bressington et al (2015) | Retrospective mirror-image observational study assessing the effects of PP-1M on acute inpatient hospitalization rates | ≥1 year | 66 | • The mean number of acute admissions fell from 0.86 in the year before PP initiation to 0.23 in the following year ($P=0.001$). |
| Doshi et al (2015) | Observational, claims-based study examining frequency and duration of concurrent oral prescriptions in patients receiving long-acting injectable formulations of antipsychotics (first and second generation) with a recent history of nonadherence and hospitalization for SZ | NA | 340 | NA | • The lowest rate of concurrent oral prescribing (58.8%) was found with PP, whereas the highest rate was with RLAi (88.9%). |
| Schreiner et al (2014) | OL study assessing tolerability, safety, and efficacy of flexible doses of PP-1M in a subset of nonacute but symptomatic SZ patients previously unsuccessfully treated with OA | 6 months | 593 | PP dose received (deltoid) of 150 mg eq. on day 1 and 100 mg eq. on day 8. Thereafter, patients received (either deltoid or gluteal) PP dose of 50-150 mg eq. on days 38, 68, 98, 128, and 158. | • PANSS total scores decreased from 71.5 (14.6) at baseline to 59.7 (18.1) at end point ($P<0.0001$). • PSP score improved significantly from baseline to end point ($P<0.0001$). |
| Schreiner et al (2015) | In subset of Schreiner et al (2014) sample (ie, patients who switched to PP-1M after unsuccessful treatment with RLAi or conventional depot antipsychotics) | 231 | • Significant reductions in PANSS total score were observed after switching ($P=0.01$). |
| Reference                 | Study Type                          | Duration | Study Duration | Participants | Effect | Findings                                                                                                                                                                                                 |
|---------------------------|-------------------------------------|----------|----------------|--------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hargarter et al (2015)    | In subset of Schreiner et al (2014) sample (i.e., patients with acute symptoms of SZ following switching from previously unsuccessful treatment with oral antipsychotics who were switched to PP-1M) | 212      |                |              |       | Significant improvements in PANSS total score were observed from day 8 onwards ($P<0.0001$). PP was also associated with significant improvements in secondary measures of symptom severity, subjective well-being, medication satisfaction, illness-related disorders of activity and participation, and patient functioning ($P<0.0001$). PP was generally well tolerated, with significant reductions in Extrapyramidal Symptom Rating Scale total score ($P<0.0001$). Most frequently reported emergent adverse events were extrapyramidal disorder (15.3%), akathisia (10.5%), blood prolactin increase (8.8%), and insomnia (5.4%). Eight deaths were reported, including four completed suicides. |
| Zhao et al (2017)          | OL study evaluating safety and efficacy of PP-1M | 25 weeks | 353            | PP dose of 150 mg eq. received (deltoid) on day 1 and 100 mg eq. received (deltoid) on day 8. Thereafter, patients received (either deltoid or gluteal) flexi doses of 75, 100, or 150 mg eq. |       | PANSS total scores improved significantly ($P<0.0001$), as did PSP scores ($P<0.0001$). In the first 12 months after hospital discharge, the risk of rehospitalization and emergency room use was significantly lower in the PP-1M cohort than in the oral antipsychotic cohort ($P<0.0001$). Institutional costs during the first 6 months after discharge were significantly lower in the PP-1M cohort ($P<0.0001$). There was a significant decrease in serum prolactin levels ($P=0.04$) and a fourfold reduction in clinically significant sexual dysfunction. |
| Lafeuille et al (2015)     | A retrospective study comparing data on re-hospitalization patterns and associated institutional costs after inpatient treatment with PP-1M or OA | 6–12 months | 45 625 | NA |       | Emergency room visits and hospitalization rates were lower in PP-1M patients, although hospitalizations did not achieve statistical significance. |
| Montalvo et al (2013)      | Prospective observational study assessing effect of switching from RLAi to PP-1M on sexual function and prolactin levels in patients with psychosis who developed hyperprolactinemia on RLAi and who were then switched to PP | 3 months | 11          | NA |       | After 1 year, 65% of patients were still receiving PP. The number of admissions to hospital in the year following PP initiation was 0.49/patient compared with 0.69/patient/year for the 3 years before initiation ($P=0.0001$). The median number of bed days for the 3 years before PP initiation was 21.50/year and in the year following PP initiation, it was 0. About 38.7% completed 2 years of continuous treatment and a further 7.6% patients discontinued PP but restarted after >2 months. Prior treatment with risperidone reduced the risk of discontinuation by 39% ($P=0.004$) and having treatment initiated as an outpatient by 49% ($P=0.011$). The risk of discontinuation was increased by 63% when the reason for prescribing PP was poor tolerability of prior treatment ($P=0.028$). |
| Morrato et al (2015)       | Retrospective, observational cohort study using patient claims data comparing effectiveness evidence for PP-1M vs atypical OA | NA       | NA           | NA |       |       |
| Taylor and Olofinjana (2014) | Observational study patients prescribed PP in normal practice were followed | 1 year   | 200          | NA |       |       |
| Taylor et al (2016)        | Observational study of patients treated with PP-1M | 2 years  | 300          | NA |       |       |
Table 3 (Continued)

| Source          | Brief description of study                                                                 | Follow-up period | Sample size, N | Treatment/intervention | Outcomes                                                                                                                                 |
|-----------------|-------------------------------------------------------------------------------------------|------------------|----------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Taylor et al    | A part-prospective mirror-image study examining outcomes of patients receiving PP-1M    | 2 years prior to PP-1M initiation and 2 years after initiation | 225            | NA                     | • At study end point, 41.8% of patients were still receiving PP-1M.                                                                       |
|                 |                                                                                            |                  |                |                        | • The number of admissions fell from 1.80 in the 2 years before starting PP-1M to 0.81 in 2 years following initiation or discharge (P<0.001). |
|                 |                                                                                            |                  |                |                        | • Total bed days were reduced from 79.6 in the 2 years before to 46.2 in the 2 years after initiation or discharge (P<0.001).             |
| Voss et al      | Study assessing elapse risk following switch from RLAi to PP-1M vs a switch from RLAi to OA | NA               | 319            | NA                     | • Patients who switched from RLAi to PP had fewer events (hospitalization or emergency room visit) (26 vs 32), longer time to an event (mean 70 vs 47 days), and lower risk of relapse (P=0.02) compared with those who switched from RLAi to oral antipsychotics. |
| Whale et al     | Naturalistic study assessing patients who initiated PP-1M                                  | 12 months        | 179            | NA                     | • About 60% of patients continued PP-1M beyond 12 months.                                                                             |
|                 |                                                                                            |                  |                |                        | • SZ diagnosis, fewer inpatient days after initiation, dose adjustment up or down, and a higher maintenance dose were associated with treatment continuation. |
| Zhang et al     | OL noncomparative study assessing patients with recent-onset SZ who were unsatisfactorily treated with previous OA switched to flexible doses of PP-1M | 18 months        | 521            | NA                     | • PANSS total scores improved significantly (P<0.0001).                                                                              |
|                 |                                                                                            |                  |                |                        | • There were greater improvements among patients with more severe symptoms.                                                            |
|                 |                                                                                            |                  |                |                        | • In a mirror analyses subset (n=474), PP significantly reduced mean number of hospitalization days/person/year as well as percentage of patients requiring hospitalization in past 12 months (P<0.0001). |
|                 |                                                                                            |                  |                |                        | • Adverse events (≥15%) were EPS (31.3%), injection site pain (18.6%), and insomnia (15.2%).                                             |
| Pesa et al      | Retrospective claims-based analysis of Medicaid patients with SZ comparing all-cause health care utilization and costs between patients treated with PP-1M vs atypical OA | 12 months        | 1,444          | NA                     | • PP-1M patients vs patients assigned to the atypical OA cohort, were less likely to discontinue treatment (30.6% vs 39.5%, P<0.001) or switch to a new therapy (21.6% vs 27.7%, P=0.007) and had fewer inpatient visits (5.0 vs 7.9, P<0.001), lower mean hospitalization days (15.0 vs 27.7 days, P<0.001), and inpatient costs (US$5,060 vs US$10,880, P=0.001). |
|                 |                                                                                            |                  |                |                        | • Pharmacy costs were significantly higher in the PP-1M cohort (P<0.001), although total costs were not significantly different (P=0.853). |
| Pilon et al     | Study comparing patients with recent-onset SZ on PP-1M vs OA in terms of adherence, health care resource utilization, and Medical aid spending | NA               | 24,300         | NA                     | • Patients treated with PP-1M had better adherence (P<0.001) and required less use of concomitant psychiatric medications. |
|                 |                                                                                            |                  |                |                        | • Lower medical costs associated with PP-1M outweighed the higher pharmacy costs, with similar total health care costs across the groups. |
| Emsley et al    | Multicenter, retrospective chart review of medical records of adult patients who were newly diagnosed with SZ who had received continuous treatment with PP-1M in naturalistic clinical settings | ≥12 months       | 84             | NA                     | • Of the patients, 79.2% had ≥20% improvement and 47.2% had a ≥50% improvement in PANSS total scores. PSP score improved significantly in 53.3%. |
|                 |                                                                                            |                  |                |                        | • Most adverse drug reactions were of mild or moderate severity.                                                                       |

Note: Phase IV study.
Abbreviations: eq., equivalent; PP, paliperidone palmitate; PP-1M, paliperidone palmitate once-monthly; RLAi, risperidone long-acting injection; OA, oral antipsychotic; PANSS, Positive and Negative Syndrome Scale; EPS, emergent extrapyramidal symptoms; OL, open-label; SZ, schizophrenia; NA, not applicable; PSP, Personal and Social Performance Scale.
domain score reductions were greater in PP-3M than placebo ($P=0.01$). In the double-blind phase, the most frequently reported adverse events in the PP-3M vs placebo groups were headache (9% vs 4%), weight gain (9% vs 3%), nasopharyngitis (6% vs 1%), and akathisia (4% vs 1%).

A double-blind RCT was designed to test the noninferiority of PP-3M formulation to PP-1M in 1,016 patients with schizophrenia who were previously stabilized on PP-1M. After screening and a 17-week, flexible-dosed, open-label phase, clinically stable patients were randomized to PP-3M (fixed-dose, 175, 263, 350, or 525 mg eq. deltoid/gluteal) or PP-1M (fixed-dose, 50, 75, 100, or 150 mg eq. deltoid/gluteal) for a 48-week double-blind phase. PP-3M was noninferior to PP-1M insofar as relapse rates were similar in both groups (8% vs 9%), as were PANSS total score changes and PSP score changes. There were no clinically relevant differences in pharmacokinetic exposure between PP-3M and PP-1M. Both groups had similar tolerability profiles with weight gain as the most common treatment-emergent adverse event. A post hoc analysis assessed the rates of symptomatic and functional remission achieved following PP-3M vs PP-1M treatment in the same sample. In the PP-3M group, 50.3% achieved symptomatic remission vs 50.8% in the PP-1M group. Functional remission was achieved in 42.5% in the PP-3M group and 43.9% in the PP-1M group. Another post hoc analysis of a subset of patients from the same study assessed 510 East Asian participants. Again, the percentage of patients who relapsed was similar for PP-3M (10.2%) and PP-1M (11.8%), as was symptom reduction. Results from the abovementioned pivotal Phase III RCTs indicate that PP-3M was efficacious and generally well tolerated. The most frequently reported adverse events were anxiety, insomnia, weight gain, nasopharyngitis, and headache. While prolactin levels were increased, there was a low incidence of prolactin-related adverse events.

In a post hoc study to evaluate the time to relapse following treatment discontinuation with oral paliperidone, PP-1M and PP-3M data were drawn from three similarly designed relapse prevention, placebo-controlled RCTs (n=449). Median (95% CI) days to relapse were 58 days (42–114 days) for oral paliperidone, 172 days (134–222 days) for PP-1M, and 395 days (274 days–not reached) for PP-3M ($P<0.0001$). The delayed time to relapse for the LAI PP formulations, particularly PP-3M, may be important in clinical practice where treatment gaps frequently occur (Table 4).

**Discussion and conclusion**

Taken together, the abovementioned studies suggest that PP has good efficacy compared with placebo and is comparable

---

**Table 4. Summary of studies with 3-monthly paliperidone palmitate**

| Source | Brief description of study | Follow-up period | Sample size, N | Treatment/intervention | Outcomes |
|--------|--------------------------|-----------------|--------------|------------------------|----------|
| Berwaerts et al (2015) | RCT comparing PP-3M/placebo | Phase I (3 weeks screening) | 506 | NA | - In the preplanned interim analysis, time to relapse was significantly longer in the PP-3M group vs placebo group ($P=0.001$), and PANSS total score and factor analysis derived domain score reductions were greater in PP-3M than placebo ($P<0.01$). - In Phase III, the most frequently reported adverse events in the PP-3M vs placebo groups were headache (9% vs 4%), weight gain (9% vs 3%), nasopharyngitis (6% vs 1%), and akathisia (4% vs 1%). |
| Savitz et al (2016) | RCT comparing PP-3M/PP-1M | Phase I (17 weeks screening) | 1,016 | PP-3M doses of 175, 263, 350, or 525 mg eq., or placebo received | - PP-3M was noninferior to PP-1M insofar as relapse rates were similar in both groups (8% vs 9%), as were PANSS total score changes and PSP score changes. - After Phase I, clinically stable patients were randomized to PP-3M fixed dose of 175, 263, 350, or 525 mg eq. or placebo received (either deltoid or gluteal muscle). - PP-3M received on day 92 (either deltoid or gluteal) or placebo received on day 64. - Single dose PP-3M (which is 3.5× stabilized dose of PP-1M received on day 92) or placebo received on day 64. - PP-1M received on day 1, 100 mg eq. received (deltoid) on day 8, and flexible doses received (deltoid or gluteal) of 50, 75, 100, or 150 mg eq. on days 36 and 64, and on day 92 the same dose as received on day 64. - In Phase III, the most frequently reported adverse events in the PP-3M vs placebo groups were headache (9% vs 4%), weight gain (9% vs 3%), nasopharyngitis (6% vs 1%), and akathisia (4% vs 1%). |

(Continued)
| Source (year) | Brief description of study | Follow-up period | Sample size, N | Treatment/intervention | Outcomes |
|---------------|----------------------------|------------------|----------------|------------------------|----------|
| Savitz et al (2017)<sup>30</sup> | Post hoc analysis assessing rates of symptomatic and functional remission achieved following PP-3M vs PP-1M treatment in the same sample as Savitz et al (2016).<sup>29</sup> | Phase II (48 weeks DB) | NA | PP-1M fixed dose of 50, 75, 100, or 150 mg eq. received (deltoid or gluteal) during Phase II | • There were no clinically relevant differences in pharmacokinetic exposure between PP-3M and PP-1M.  
 • Both groups had similar tolerability profiles with weight gain as the most common treatment-emergent adverse event.  
 • In the PP-3M group, 50.3% achieved symptomatic remission vs 50.8% in the PP-1M group.  
 • Functional remission was achieved in 42.5% in the PP-3M group and 43.9% in the PP-1M group. |
| Savitz et al (2017)<sup>31</sup> | Post hoc analysis conducted in subset of sample from Savitz et al (2016).<sup>29</sup> | 510 | • The percentage of patients who relapsed was similar for PP-3M (10.2%) and PP-1M (11.8%) groups, as was symptom reduction. |
| Weiden et al (2017)<sup>33</sup> | Post hoc study evaluating time to relapse following treatment discontinuation with oral paliperidone, PP-1M, and PP-3M<sup>a</sup> | NA | 449 | NA | • Median days to relapse were 58 days for oral paliperidone, 172 days for PP-1M, and 395 days for PP-3M (P<0.0001). |

Note: Data were drawn from three similarly designed relapse prevention, placebo-controlled RCTs.

**Abbreviations:** eq., equivalent; RCT, randomized controlled trial; PP-1M, paliperidone palmitate once-monthly; PP-3M, paliperidone palmitate 3-monthly; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social Performance Scale; OL, open-label; DB, double-blind; NA, not applicable.
with risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Particularly in the early stages of illness, these side effects may be a significant barrier to effective treatment. Prolactin-related sexual dysfunction may be particularly relevant to younger people, and so too excessive weight gain.

Compared with RLAI, PP offers advantages of not requiring refrigeration or reconstitution prior to administration, or special needle kits. Additional advantages of PP include the following: First, there is a wealth of research data and clinical experience for both risperidone and paliperidone, so that the efficacy, safety, and tolerability profile of the compound is well known. Second, the availability of different formulations (PP-1M, PP-3M, and perhaps even longer-acting formulations in future) provides clinicians and patients with a variety of treatment options. A longer interval between injections may be important when aiming for recovery, where patient autonomy and independent living are key considerations. Third, injections may be given in either the deltoid or gluteal muscles, which may be of importance to some patients. Finally, the PP-1M dose-initiation procedure provides rapid onset of action, thereby circumventing the need for oral supplementation and enabling its use in acute settings. The importance of adhering to the recommended initiation dosing regimen needs to be emphasized. Earlier studies suggested that using a lower initial dose may compromise the early treatment response. Subsequent carefully conducted clinical trials and pharmacokinetic data confirmed the importance of the initial loading doses. In conclusion, PP is an important treatment option available to patients with schizophrenia and related illness, although cost considerations limit its use in resource-constrained environments.

Disclosure
In the past 3 years, Robin Emsley has participated in speakers/advisory boards and received honoraria from Janssen, Lundbeck, Servier, and Otsuka. He has also received research funding from Janssen and Lundbeck. Sanja Kilian reports no conflicts of interest in this work.

References
1. Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373.
2. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449.
3. Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1–3):117–121.
4. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913–920.
5. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
6. Zipursky RB, Menezes NM, Steiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2–3):408–414.
7. Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy. 2015;35(9):813–822.
8. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
9. Owen MJ, O’Donovan MC. Schizophrenia and the neurodevelopmental continuum: evidence from genomics. World Psychiatry. 2017;16(3):227–235.
10. McGlashan TH. Is active psychosis neurotoxic? Schizophr Bull. 2006;32(4):609–613.
11. Morgan C, Lappin J, Heslin M, et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol Med. 2014;44(13):2713–2726.
12. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50(5):369–376.
13. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1–3):129–139.
14. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.
15. Swartz MS, Stroup TS, McEvoy JP, et al. What CATIE found: results following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 2007;64(1):50–56.
16. Pousa E, Ochoa S, Cobo J, et al. A deeper view of insight in schizophrenia: insight dimensions, unawareness and misattribution of particular symptoms and its relation with psychopathological factors. Schizophr Res. 2017;189:61–68.
17. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv. 2004;55(9):997–1005.
18. Emsley R, Chiliza B, Asmal L, Mshale M, Fursa-Poi P. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013;7(3):247–254.
19. Jiang Y, Ni W. Health care utilization and treatment persistence associated with oral paliperidone and lurasidone in schizophrenia treatment. J Manag Care Spec Pharm. 2015;21(9):780–792.
20. Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15(2):163–174.
21. Invega Sustain™ [Product Monograph]. Markham, ON: Janssen-Ortho Inc; 2010.
22. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51(1):80–88.
23. Clenton A, Rossenu S, Cruwels H, et al. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol. 2014;54(9):1048–1057.
24. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635–647.
25. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35(10):2072–2082.
26. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. *Int Clin Psychopharmacol*. 2010;25(5):247–256.

27. Pandina GJ, Lindemmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. *J Clin Psychopharmacol*. 2010;30(3):235–244.

28. Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. *Ann Gen Psychiatry*. 2011;10(1):12.

29. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. *Schizophr Res*. 2010;116(2–3):107–117.

30. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. *J Psychopharmacol*. 2011;25(5):685–697.

31. Fu DJ, Turkoe I, Walling D, Lindemmayer JP, Schooller NR, Alphs L. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizophrenia. *Schizophr Res*. Epub 2017 Apr 25.

32. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. *Int J Neuropsychopharmacol*. 2012;15(1):107–118.

33. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(1):218–226.

34. Fu DJ, Bossie CA, Kern SJ, Ma YW, Alphs L. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. *Clin Schizophr Relat Psychoses*. 2014;8(2):101–109, 109A.

35. Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. *Int Clin Psychopharmacol*. 2014;29(1):45–55.

36. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(4):1002–1008.

37. Koshiyama Y, Takekita Y, Kato M, et al. The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled pilot trial. *Neuropsychobiology*. 2016;73(1):35–42.

38. Takekita Y, Koshiyama Y, Fabbi C, et al. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized pilot trial. *BMJ Psychiatry*. 2016;16:172.

39. Alphs L, Mao L, Lynn SH, Benson C. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia. *Schizophr Res*. 2016;170(2–3):259–264.

40. Kwon JS, Kim SN, Han J, et al. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. *Int Clin Psychopharmacol*. 2015;30(6):320–328.

41. Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. *Schizophr Res*. 2015;168(1–2):498–504.

42. McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. *JAMA*. 2014;311(19):1978–1987.

43. Rosenheck RA, Leslie DL, Sint KJ, et al. Cost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophrenia. *Psychiatr Serv*. 2016;67(10):1124–1130.

44. Scherina A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. *Schizophr Res*. 2015;169(1–3):393–399.

45. Gopal S, Xu H, McQuarrie K, et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. *NPJ Schizophr*. 2017;3(1):23.

46. Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Paliperidone palmitate-long acting injection – prospective year-long follow-up of use in clinical practice. *Acta Psychiatr Scand*. 2014;130(1):46–51.

47. Hargarter L, Lahaye M, Cherubin P, et al. Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia. *World J Biol Psychiatry*. Epub 2017 Jun 8.

48. Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. *J Med Econ*. 2015;18(5):357–365.

49. Bressington D, Stock J, Hulbert S, MacInnes D. A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. *Int Clin Psychopharmacol*. 2015;30(4):230–236.

50. Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge. *J Clin Psychopharmacol*. 2015;35(4):442–446.

51. Schreiner A, Bergmans P, Cherubin P, et al. A prospective flexible-dose study of paliperidone palmitate in nonacuate but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. *Clin Ther*. 2014;36(10):1372–1388.

52. Schreiner A, Bergmans P, Cherubin P, et al. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. *J Psychopharmacol*. 2015;29(8):910–922.

53. Hargarter L, Cherubin P, Bergmans P, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015;58:1–7.

54. Zhao J, Li L, Shi J, et al. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. *Neuropsychiatr Dis Treat*. 2017;13:2045–2056.

55. Lafuitt MH, Gritter AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. *Am J Health Syst Pharm*. 2015;72(5):378–389.

56. Montalvo I, Ortega L, Lopez X, et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from paliperidone palmitate vs haloperidol decanoate for maintenance treatment of acutely exacerbated schizophrenia. *Syst Pharm*. 2016;910–922.

57. Moratto EH, Parks J, Campagna EJ, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. *J Comp Eff Res*. 2015;4(2):89–99.

58. Taylor D, Olofinjana O. Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization. *Int Clin Psychopharmacol*. 2014;29(4):229–234.
59. Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Paliperidone palmitate: factors predicting continuation with treatment at 2 years. *Eur Neuropsychopharmacol*. 2016;26(12):2011–2017.

60. Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort—a four-year mirror image study. *Eur Psychiatry*. 2016;37:43–48.

61. Voss EA, Ryan PB, Stang PE, Hough D, Alphs L. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. *Int Clin Psychopharmacol*. 2015;30(3):151–157.

62. Whale R, Pereira M, Cuthbert S, Fialho R. Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study. *J Clin Psychopharmacol*. 2015;35(5):591–595.

63. Zhang F, Si T, Chiou CF, et al. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. *Neuropsychiatr Dis Treat*. 2015;11:657–668.

64. Pesa JA, Doshi D, Wang L, Yuce H, Baser O. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. *Curr Med Res Opin*. 2017;33(4):723–731.

65. Pilon D, Muser E, Lefebvre P, Kamstra R, Emond B, Joshi K. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment. *BMC Psychiatry*. 2017;17(1):207.

66. Emsley R, Hargarter L, Bergmans P, et al. Once-monthly paliperidone palmitate in early stage schizophrenia—a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. *Neuropsychiatr Dis Treat*. 2017;13:2261–2269.

67. Carpiello B, Pina F. Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia. *Drug Des Devel Ther*. 2016;10:1731–1742.

68. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(8):830–839.

69. Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. *Int J Neuropsychopharmacol*. 2016;19(7).

70. Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. *Int Clin Psychopharmacol*. 2017;32(6):329–336.

71. Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. *Neuropsychiatr Dis Treat*. 2017;13:2193–2207.

72. Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: a review in schizophrenia. *Drugs*. 2016;76(16):1559–1566.

73. Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. *J Clin Psychiatry*. 2017;78(7):e813–e820.